Efektivitas Dan Keamanan Vaksin Covid-19 : Studi Refrensi

DOI: https://doi.org/10.33650/jkp.v9i2.2767

Authors (s)


(1) * Setiyo Adi Nugroho   (Universitas Nurul Jadid, Probolinggo)  
        Indonesia
(2)  Indra Nur Hidayat   (Universitas Nurul Jadid, Probolinggo)  
        Indonesia
(*) Corresponding Author

Abstract


Various strategies and development of the Covid-19 vaccine have been carried out for the control of the Covid-19 pandemic. Various vaccines have undergone clinical trials with promising results in various countries. The effectiveness and safety and short- and long-term side effects of vaccines are a major concern in clinical trials in these strategies and developments. Purpose: The purpose of this study is to find out the effectiveness and safety of the Covid-19 vaccine so that it can inform and increase public confidence in the Covid-19 vaccine through a reference study approach. Method: The research method we use here is a reference study using electronic databases through journals from international and national. Google Scholar, science direx, elsiver, Pubmed are used as the main Journal database for this reference study. Results: From the results of reference studies found that all vaccines in clinical trials have promising effectiveness and safety. The Pfizer-BiONTech vaccine is a vaccine that has a good level of effectiveness and safety with a value of 94.6% and does not cause serious side effects. Double-dose vaccination further improves the immune response in younger and older adults. Conclusion: The Covid-19 vaccine in clinical trials all demonstrates promising immunogenicity with varying levels of protective effectiveness and an acceptable safety profile.



Keywords

Covid-19. Vaccine. Effectiveness. Safety



Full Text: PDF



Article View

Abstract views : 8414 times | PDF files viewed : 31922 times

Dimensions, PlumX, and Google Scholar Metrics

10.33650/jkp.v9i2.2767


Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Setiyo Adi Nugroho, Indra Nur Hidayat

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.